Search results
Found 1079 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Women are majorly under-represented in COVID-19 research authorship
Coronavirus COVID-19 General Research
12 June 2020
New research from The George Institute for Global Health at the University of Oxford has found significant gender bias in research authorship relating to COVID-19, which means that women’s views are not equally shaping the response to the pandemic.
Oxford researchers awarded funding to unlock disease biology
Awards and Appointments General Research
10 June 2020
Oxford Structural Genomics Consortium (SGC) is a key member of a new EUbOPEN consortium which has been awarded funding from the Innovative Medicines Initiative to develop openly available chemical tools for understanding human biology.
The neurobiology of social distance: why loneliness may be the biggest threat to survival
Coronavirus COVID-19 General Research
8 June 2020
Never before have we experienced social isolation on a massive scale as we have during the evolving COVID-19 pandemic.
New resources on talking to children about illness and death during the COVID-19 pandemic
Coronavirus COVID-19 General Research
5 June 2020
The news that children currenty face may seem almost unspeakable. But, together, we must find words, and ways, to give voice to their experience and prevent millions of children struggling with their fears and uncertainty alone.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.
Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.
Bacteria perform mass suicide to defend their colony
General Research
5 June 2020
A new study from researchers at Oxford University’s Departments of Zoology and Biochemistry shows that warring bacteria will engage in suicidal attacks in vast numbers to take down competitors.
Oxford University’s COVID-19 vaccine: next steps towards broad and equitable global access
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
Brazilian Health Regulatory Agency approves trial of Oxford COVID-19 Vaccine
Clinical Trials Coronavirus COVID-19 General Research
4 June 2020
On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
First patient recruited in key COVID-19 drug treatment trial
Clinical Trials Coronavirus COVID-19 General Research
4 June 2020
A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.
New research finds half of UK parents uncomfortable with children returning to school
Coronavirus COVID-19 General Research
3 June 2020
Half of UK parents do not feel comfortable about their children attending school following lockdown, according to early results from a new study asking parents and carers about their children’s mental health through the COVID-19 crisis.
Nicotine therapy for coronavirus: the evidence is weak and contradictory
Coronavirus COVID-19 General Research
3 June 2020
First patient, a child, receives convalescent plasma through RECOVERY, the dedicated COVID-19 treatment trial
Clinical Trials Coronavirus COVID-19 General Research
3 June 2020
The first person to be randomly selected to receive convalescent plasma through RECOVERY has now received a transfusion.
Coronavirus and diabetes: the different risks for people with type 1 and type 2
Coronavirus COVID-19 General Research
2 June 2020
Coronavirus: is it safe for children to return to school?
Coronavirus COVID-19 General Research
2 June 2020
The Duke of Westminster donates £1m to Oxford University’s COVID-19 mental health research
Awards and Appointments Coronavirus COVID-19 General Research
29 May 2020
Hugh Grosvenor, The Duke of Westminster, has donated £1m towards Oxford University’s COVID-19 mental health research programmes. This is part of the £10m donation announced by the Westminster Foundation last month to support the national COVID-19 relief effort.
COVID-19 drug trial could lead to enhanced respiratory care for patients
Clinical Trials Coronavirus COVID-19 General Research
29 May 2020
Researchers at the University of Oxford are working with clinical collaborators from NHS hospitals to carry out a new clinical drug trial aimed at treating COVID-19, funded by LifeArc. It will test a drug that could raise oxygen levels in the blood in COVID-19 patients in order to improve their chances of recovery. Raising oxygen levels is important in COVID-19, because many patients with the disease die when oxygen levels in their arterial blood fall to levels that are too low to support life.
HCQ with antibiotics to treat COVID-19 could be dangerous for the heart
Coronavirus COVID-19 General Research
27 May 2020
Researchers from the Department of Physiology, Anatomy & Genetics (DPAG) have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.